Clinical Trial Update: Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial exploring a combination of Camrelizumab and Apatinib for downstaging bridging to liver transplant in hepatocellular carcinoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Zhejiang University | Conditions: Hepatocellular Carcinoma, Liver Transplant | Phase 1, Phase 2 | Status: UNKNOWN